A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

Abstract Background Cancer stem cells (CSCs) are purported to be responsible for tumor initiation, treatment resistance, disease recurrence, and metastasis. CXCR1, one of the receptors for CXCL8, was identified on breast cancer (BC) CSCs. Reparixin, an investigational allosteric inhibitor of CXCR1,...

Full description

Bibliographic Details
Main Authors: Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato, Jenny C. Chang
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Breast Cancer Research
Subjects:
Cancer stem cells
CXCR1
Reparixin
Autophagy
Online Access:https://doi.org/10.1186/s13058-019-1243-8

Internet

https://doi.org/10.1186/s13058-019-1243-8

Similar Items